Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409586 | 0.89 | LSS (0.56) | CYP3A4CYP2D6KDM4ELSS | |
| SCHEMBL13391205 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL13409072 | 0.87 | CYP3A4 (0.53) | CYP3A4 | |
| SCHEMBL13409046 | 0.86 | ALDH1A1 (0.48) | CYP3A4CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL14456755 | 0.86 | CYP3A4 (0.65) | CYP3A4CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL14078067 | 0.85 | CYP3A4 (0.57) | CYP3A4CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL14387692 | 0.84 | CYP3A4 (0.56) | CYP3A4CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL13409748 | 0.83 | CYP3A4 (0.46) | CYP3A4CYP2D6MEN1TSHRKMT2A | |
| SCHEMBL14456892 | 0.82 | MEN1 (0.63) | CYP3A4CYP2D6ALDH1A1MEN1TSHR | |
| SCHEMBL14355764 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP2D6KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | CYP3A4 2573/4885CYP2D6 1986/4885KDM4E 2918/4885 |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | HRH2, HRH1, HRH4 | CYP3A4 938/4885CYP2D6 884/4885KDM4E 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.